Medtronic Summary


Medtronic is a company that develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, cardiac resynchronization therapy devices, AF ablation and TYRX products, as well as remote monitoring and patient-centered software. The Minimally Invasive Therapies Group segment provides surgical products, electrosurgical hardware and instruments, mesh fixation devices, gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons, neurosurgeons, pain management specialists, anesthesiologists, and interventional radiologists, and provides image-guided surgery and intra-operative imaging systems and robotic guidance systems. The Diabetes Group segment provides insulin pumps and consumables, and continuous glucose monitoring systems.
HQDublin, IEMap
Overall CultureC+More


Medtronic is headquartered in
Dublin, Ireland

Location Map

Latest Updates

Company Growth (employees)

Employees (est.) (Apr 2020)90,000
Job Openings2,553
Website Visits (Apr 2021)3 m(-4%)
Revenue (FY, 2020)$28.9 B(-5%)
Share Price (Jun 2021)$123.8
Cybersecurity ratingCMore

Key People/Management at Medtronic

Medtronic Office Locations

Medtronic has offices in Dublin, Boulder, Doral, Fridley and in 72 other locations

Medtronic Financials and Metrics

Medtronic Revenue

Medtronic's revenue was reported to be $28.91 b in FY, 2020 which is a 5.4% decrease from the previous period.


Revenue (Q3, 2021)$7.78 b
Gross profit (Q3, 2021)$5.15 b
Gross profit margin (Q3, 2021), %66.3%
Net income (Q3, 2021)$1.28 b
EBIT (Q3, 2021) $1.28 b
Market capitalization (11-Jun-2021)$166.86 b
Closing stock price(11-Jun-2021)$123.78
Cash (29-Jan-2021)$5.08 b
EV $192.11 b

Medtronic's current market capitalization is $166.9 b.

USDFY, 2018FY, 2019FY, 2020
Revenue30 b30.6 b28.9 b
Revenue growth, %1%2%(5%)
Cost of goods sold9.1 b9.2 b9.4 b
Gross profit20.9 b21.4 b19.5 b
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021
Revenue7.4 b7.5 b7.5 b7.5 b7.7 b7.7 b6.5 b7.6 b7.8 b
Cost of goods sold2.2 b2.2 b2.3 b2.4 b2.4 b2.4 b2.5 b2.7 b2.6 b
Gross profit5.2 b5.3 b5.3 b5.1 b5.3 b5.3 b4 b4.9 b5.2 b
Gross profit Margin, %70%71%70%68%69%69%62%65%66%
show all

USDFY, 2018FY, 2019FY, 2020
Cash3.7 b4.4 b4.1 b
Accounts Receivable6 b6.2 b4.6 b
Inventories3.6 b3.8 b4.2 b
Current Assets23 b22 b22 b
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021
Cash4.4 b3.9 b3.7 b5.1 b4 b3.7 b6.5 b6.4 b5.1 b
Accounts Receivable5.7 b5.7 b5.9 b5.9 b6.1 b6.2 b4.9 b5.3 b5.2 b
Inventories3.7 b3.8 b3.9 b3.9 b4 b4.1 b4.6 b4.5 b4.5 b
Current Assets22.5 b21.7 b20.9 b22.7 b22.7 b24 b24.5 b26 b26.3 b
show all

USDFY, 2018FY, 2019FY, 2020
Net Income3.1 b4.7 b4.8 b
Depreciation and Amortization2.6 b2.7 b2.7 b
Accounts Receivable(275 m)(581 m)1.3 b
Inventories(192 m)(274 m)(577 m)
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021
Net Income1.1 b2.2 b3.5 b877 m2.2 b4.2 b491 m985 m2.3 b
Depreciation and Amortization666 m1.3 b2 b657 m1.3 b2 b669 m1.3 b2 b
Accounts Receivable138 m(37 m)(140 m)319 m39 m(119 m)(142 m)(669 m)(450 m)
Inventories(180 m)(312 m)(367 m)(122 m)(267 m)(346 m)(235 m)(145 m)(75 m)
show all

Q3, 2021
EV/EBIT140.7 x
EV/CFO40.0 x
Debt/Equity0.6 x
Debt/Assets0.3 x
Financial Leverage1.9 x
P/E Ratio122.1 x
  • Medtronic Market Cap History

  • Medtronic Stock Price

Revenue Breakdown

Medtronic revenue breakdown by business segment: 8.2% from Diabetes Group, 28.9% from Minimally Invasive Therapies Group, 36.2% from Cardiac and Vascular Group and 26.7% from Restorative Therapies Group

Medtronic revenue breakdown by geographic segment: 51.6% from United States, 32.1% from Non-U.S. Developed Markets and 16.3% from Emerging Markets

Medtronic Operating Metrics

Medtronic's Floor Space, square feet was reported to be 9.4 m in FY, 2020.

FY, 2015FY, 2016FY, 2017FY, 2018Jun, 2019FY, 2019FY, 2020
Manufacturing Facilities8089
Sales Offices345224189180
Floor Space, square feet9 m9.4 m

Medtronic Acquisitions / Subsidiaries

Company NameDateDeal Size
Ai BiomedOctober 29, 2020
Companion MedicalAugust 11, 2020
MedicreaJuly 15, 2020
Digital SurgeryFebruary 13, 2020
StimgenicsJanuary 08, 2020
KlueDecember 17, 2019
AV MedicalOctober 11, 2019$30 m
Titane SpineMay 10, 2019
EPIX TherapeuticsJanuary 24, 2019
NutrinoNovember 30, 2018

Human Capital Metrics


Medtronic Hiring Categories

Medtronic Median Salaries

Source: 9 public H-1B filings from Medtronic

Medtronic Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Medtronic Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset


out of 100

CSRHub logo

Medtronic Website Traffic

Alexa Website Rank

Total Visits per monthSimilarWeb

Medtronic Online and Social Media Presence

Twitter followers

77.45 k Twitter followers

6 Months

Medtronic has 77.45 k Twitter Followers. The number of followers has increased 0.06% month over month and increased 1.45% quarter over quarter.

Medtronic's Trends

Search term - Medtronic

Twitter Engagement Stats for @Medtronic

  • 4.79 k


  • 391


  • 77.45 k


  • 64

    Tweets last 30 days

  • 6.8

    Avg. likes per Tweet

  • 50%

    Tweets with engagement

Medtronic Technology StackBuildWith Logo

  • ads

    18 products used

    • Adify
    • AdRoll
    • AppNexus
      • AppNexus Segment Pixel
      • Burst Media
      • Centro
      • Collective Media
      • DoubleClick.Net
      • Facebook Exchange FBX
      • Falk Realtime
      • Google Adsense
      • Google AdSense Custom Search Ads
      • Google Adsense for Search
      • IponWeb BidSwitch
      • Openads/OpenX
      • Pubmatic
      • Twitter Ads
      • Yahoo Small Business
  • analytics

    18 products used

    • Adobe Dynamic Tag Management
    • Adobe Target Standard
    • Dynatrace
      • Eloqua
      • Facebook Domain Insights
      • ForeSee Results
      • Google Analytics
      • Google Analytics Classic
      • Google Analytics Event Tracking
      • Google Content Experiments
      • Google Website Optimizer
      • Hotjar
      • Omniture Adobe Test and Target
      • Omniture SiteCatalyst
      • Rapleaf
      • Twitter Analytics
      • Visual Website Optimizer
      • Yahoo Web Analytics
  • cdn

    8 products used

    • AJAX Libraries API
    • Akamai
    • CloudFront
      • Content Delivery Network
      • GStatic Google Static Content
      • OSS CDN
      • Twitter CDN
      • Yahoo Image CDN
  • cdns

    1 product used

    • Akamai Edge
Learn more on BuiltWith

Medtronic Company CultureCultureAndCompensation Logo

  • Overall Culture



  • CEO Rating



  • Compensation



  • Diversity



Learn more on Comparably

Medtronic News and Updates

Jun 14, 2021
Worldwide Tricuspid Valve Repair Industry to 2025 - Featuring Abbott Laboratories, Medtronic, Edwards Lifesciences and LivaNova
DUBLIN, June 14, 2021 /PRNewswire/ -- The "Global Tricuspid Valve Repair Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to's offering. This report provides in-depth analysis of the global tricuspid valve repair, with...
Jun 14, 2021
Worldwide Vascular Stents Industry to 2026 - Featuring Medtronic, Abbott Laboratories and Boston Scientific Among Others
_3xOCqDublin, June 14, 2021 (GLOBE NEWSWIRE) -- The "Vascular Stents Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to's offering. The global vascular stents market reached a value of US$ 9.4 Billion in 2020. A vascular stent is a small device that is used to clear and prevent blockages in the heart valves and arteries. It is also used to provide internal structural support to stenotic or occluded blood vessels. The process of placing a vascular stent inside the body is known as vascular stenting. Vascular stents are usually made of polyethylene, polypropylene or non-absorbable materials such as stainless steel or cobalt-chromium alloys. They may vary from tubular stent-grafts, which are used to repair aneurysms, to expandable metal meshes that are used during percutaneous vessel interventions. Once the stent is placed in the intended location, it is expanded using a balloon or a self-expanding mechanism.Rapidly increasing geriatric population is one of the major factors driving the market growth worldwide. Furthermore, there has been a rise in the incidence rate of various ailments such as peripheral artery disease (PAD), aortic aneurysm, and ischemic heart disease. The frequent occurrence of these ailments has led to a growing requirement for vascular stents. This can be attributed to lifestyle choices such as smoking and high alcohol consumption coupled with physical inactivity and unhealthy dietary habits of individuals. Additionally, increasing consumer inclination toward minimally invasive (MI) procedures is also driving the market growth. The MI vascular stenting procedures ensure shorter hospital stay, quick recovery and greater comfort for the patients.
Jun 03, 2021
Medtronic Halts Heart Failure Device Sales as Risks Surface
_3xOCqMedtronic Halts Heart Failure Device Sales as Risks Surface
Jun 03, 2021
Medtronic to Stop Distribution and Sale of HVAD™ System
- Company Developing Support Program for Current HVAD Patients - Medtronic Coordinating with Global Regulators to Assure Patient Access to Left Ventricular Assist Devices DUBLIN, June 3, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, is stopping...
May 28, 2021
Titan Medical Receives License Fee of $10 Million Upon Achievement of Milestone Under Medtronic Development Agreement
Completion of Second Technical Milestone Marks Third Achievement Under Development and License Agreement Completion of Second Technical Milestone Marks Third Achievement Under Development and License Agreement
May 27, 2021
Medtronic beats profit and revenue expectations, boosts dividend
_3xOCqShares of Medtronic PLC slipped 0.1% in premarket trading Thursday, after the medical technology and services company reported fiscal fourth-quarter profit and sales that rose above expectations, citing a "strong recovery" in elective procedures, and boosted its dividend by 8.6%, but provided a less than upbeat full-year outlook. Net income for the quarter to April 30 rose to $1.36 billion, or $1.00 a share, from $646 million, or 48 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share grew to $1.50 from 58 cents, and beat the FactSet consensus of $1.42. Sales increased 36.5% to $8.19 billion, topping the FactSet consensus of $8.14 billion. Looking ahead, the company expects fiscal 2022 adjusted EPS of $5.60 to $5.75, compared with the FactSet consensus of $5.75. Separately, the company said it raised its quarterly dividend to 63 cents a share from 58 cents, with the new dividend payable July 16 to shareholders of record on June 25. The new annual dividend rate would lift the implied dividend yield to 2.00%, based on Wednesday's stock closing price, while the implied yield for the S&P 500 is 1.40%. The stock has gained 7.8% year to date, while the S&P 500 has advanced 11.7%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

Medtronic Blogs

Jun 10, 2021
Medtronic Announces FDA Approval of its Next Generation Recharge-Free Spinal Cord Stimulation Platform
Medtronic Announces FDA Approval of its Next Generation Recharge-Free Spinal Cord Stimulation Platform Content Import Thu, 06/10/2021 - 09:02 Medtronic Announces FDA Approval of its Next Generation Recharge-Free Spinal Cord Stimulation Platform June 10, 2021 at 9:00 AM EDT This release is a backfill from a News Wire General Vanta™ Implantable Neurostimulator Offers Up to 11 Year Battery Life and Personalized Pain Relief DUBLIN, June 10, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for Vanta™, a high performance recharge-free implantable neurostimulator (INS) with a device life that can be optimized up to 11 years. At comparable settings, the Vanta neurostimulator offers nearly twice the device life than competitive primary cell devices.1,2 It also utilizes Medtronic's proprietary AdaptiveStim™ technology for personalized pain relief that adapts to the patient's movement or body position using a built-in accelerometer. AdaptiveStim technology goes beyond in-office programming by automatically adjusting stimulation to maintain each patient's optimal dose. The Vanta neurostimulator also provides unmatched full-body MRI access with Medtronic SureScan™ technology.3 Approximately 82% of SCS-implanted patients will need at least one MRI within five years of implant.4   "Not every patient with chronic, intractable pain is an ideal candidate for a rechargeable device, so the Vanta INS represents a welcome addition to my portfolio of available treatment options," said Krishnan Chakravarthy, M.D., Ph.D., a San Diego-based interventional pain management physician. "The extended battery life, broad MRI compatibility and personalized relief through AdaptiveStim technology allow for a more hassle-free experience and greater freedom for my patients as we manage their chronic pain." Medtronic is continually innovating to advance spinal cord stimulation therapy technologies that improve quality of life for people with chronic pain. The Vanta neurostimulator represents a 10% increase in longevity compared to PrimeAdvanced™, Medtronic's previous generation recharge-free device. It is also 20% smaller than the PrimeAdvanced neurostimulator, with a more rounded, ergonomic contouring to offer enhanced comfort. The Vanta system provides access to Snapshot™ reporting, Medtronic's proprietary data insights solution, offering clinicians objective reporting of patient activity levels to empower objective health conversations. Clinicians and their patients wishing to trial the Vanta neurostimulator may also take advantage of CareGuidePro™, a mobile application and web portal that serves as a virtual guide for patients throughout their Medtronic spinal cord stimulation therapy journey. CareGuidePro is currently in limited commercial release with a full launch expected later this summer. "We are committed to delivering innovative solutions that meets the needs of every patient," said Charlie Covert, vice president and general manager, Pain Therapies within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. "For those who prefer or require a recharge-free device, I believe the Vanta neurostimulator offers the best hardware and features available today. We are pleased to offer this solution, which is now part of the strongest and broadest overall portfolio in this market." Medtronic continues to focus on expanding access to its highly effective DTM™ SCS therapy through pre-clinical and clinical work. DTM SCS is currently available on the rechargeable Intellis™ SCS platform, and the company expects to share more information about its availability across the entire Medtronic spinal cord stimulator portfolio later this summer. About Medtronic Medtronic plc (, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. References Settings used from Abbott's Proclaim™ clinician manual. Nominal settings 12 hours per day: 50-Hz frequency, 225-μs pulse width, and 5-mA amplitude at 500-ohms impedance. Compared to flagship model 3660. Settings from Boston Scientific's Alpha™ IFU. Programmed at 4.1mA, 280us, 40 Hz, 1 area, 730 Ohms, 2 contacts. Under specific conditions. Refer to product labeling for full list of conditions. Desai MJ, Hargens LM, Breitenfeldt MD, et al. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine. 2015;40(9):E531-537. Contacts: Jeff Trauring Ryan Weispfenning Public Relations Investor Relations +1-763-505-0159 +1-763-505-4626           View original content to download multimedia: SOURCE Medtronic plc Vanta™ Implantable Neurostimulator Offers Up to 11 Year Battery Life and Personalized Pain Relief DUBLIN , June 10, 2021 /PRNewswire/ --  Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for Vanta™,
Jun 07, 2021
Medtronic Insertable Cardiac Monitor Detects Significantly Higher Rates of Atrial Fibrillation in Large and Small Vessel Stroke Patients Compared to Standard of Care
Publication in JAMA Shows Reveal LINQ™ ICM Demonstrated a Seven-Fold Increase in Detecting AF vs. Standard of Care DUBLIN , June 7, 2021 /PRNewswire/ --  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced clinical trial results from the STROKE AF trial demonstrating
Jun 07, 2021
FDA Approves First-of-its-Kind SenSight™ Directional Lead System for DBS Therapy
The SenSight™ Directional Lead System Was Designed to Enable Precision, Personalization and Enhanced Patient Comfort DUBLIN , June 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) approval and
Jun 03, 2021
Medtronic Gains FDA Clearance of UNiD™ Patient-Specific Rods for Use with CD Horizon™ Solera™ Voyager™ and Infinity™ OCT Spinal Systems
Compatibility of UNiD™ Rods with Medtronic's Spinal Systems Enables the Integration of AI-Driven Surgical Planning, Patient-Specific Spinal Implants and Robotic Assisted Surgery to Improve Procedural Efficiency, Precision and Outcomes

You may also be interested in Related companies

Gala Therapeutics
Menlo Park, US
Gala Therapeutics is a medical device company developing technologies for the treatment of pulmonary diseases.
View company
Seattle, US
139  -1decrease
CorneaGen is a company that develops medical devices and therapies for the cornea.
View company
Relievant Medsystems
Bloomington, US
81  4increase
Relievant Medsystems develops therapeutic solutions to treat chronic axial low back pain.
View company
Varian Medical Systems
Palo Alto, US
10062  40increase
Varian Medical Systems is a manufacturer of medical devices and software for treating cancer and other medical conditions.
View company
When was Medtronic founded?
Medtronic was founded in 1949.
Who are Medtronic key executives?
Medtronic's key executives are Geoffrey S. Martha, Lisa Ruiz and Alex Gu.
How many employees does Medtronic have?
Medtronic has 90,000 employees.
What is Medtronic revenue?
Latest Medtronic annual revenue is $28.91 b.
What is Medtronic revenue per employee?
Latest Medtronic revenue per employee is $321.26 k.
Who are Medtronic competitors?
Competitors of Medtronic include B. Braun Melsungen, B. Braun and Orthofix.
Where is Medtronic headquarters?
Medtronic headquarters is located at 20 Lower Hatch Street, Dublin.
Where are Medtronic offices?
Medtronic has offices in Dublin, Boulder, Doral, Fridley and 73 other locations
How many offices does Medtronic have?
Medtronic has 79 offices.

Craft real-time company insights

Learn about Craft real-time company insights

Receive alerts for 300+ data fields across thousands of companies

Footer menu